Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.

Henske EP, Rasooly R, Siroky B, Bissler J.

Am J Physiol Renal Physiol. 2014 Feb 1;306(3):F279-83. doi: 10.1152/ajprenal.00525.2013. Epub 2013 Nov 13.

2.

Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.

Budde K, Gaedeke J.

Am J Kidney Dis. 2012 Feb;59(2):276-83. doi: 10.1053/j.ajkd.2011.10.013. Epub 2011 Nov 29. Review.

PMID:
22130643
3.

Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas.

Coombs EJ.

J Am Assoc Nurse Pract. 2013 Nov;25(11):588-96. doi: 10.1002/2327-6924.12081. Epub 2013 Oct 1. Review.

4.

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

MacKeigan JP, Krueger DA.

Neuro Oncol. 2015 Dec;17(12):1550-9. doi: 10.1093/neuonc/nov152. Epub 2015 Aug 19. Review.

5.

Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation.

Somers MJ, Paul E.

J Clin Pharmacol. 2015 Apr;55(4):368-76. doi: 10.1002/jcph.428. Epub 2014 Dec 30. Review.

PMID:
25402866
6.

Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex.

Peces R, Peces C, Cuesta-López E, Pérez-Dueñas V, Vega-Cabrera C, Azorín S, Selgas R.

Nephrol Dial Transplant. 2010 Nov;25(11):3787-91. doi: 10.1093/ndt/gfq456. Epub 2010 Jul 27.

PMID:
20663789
7.

Possible prevention of tuberous sclerosis complex lesions.

Kotulska K, Borkowska J, Jozwiak S.

Pediatrics. 2013 Jul;132(1):e239-42. doi: 10.1542/peds.2012-3607. Epub 2013 Jun 3.

8.

Clinical and molecular insights into tuberous sclerosis complex renal disease.

Siroky BJ, Yin H, Bissler JJ.

Pediatr Nephrol. 2011 Jun;26(6):839-52. doi: 10.1007/s00467-010-1689-5. Epub 2010 Dec 9. Review.

PMID:
21152937
9.

Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.

Kingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, Sauter M, Cox J, Patel U, Elmslie F, Anderson C, Zonnenberg BA.

Nephron. 2016;134(2):51-58. Epub 2016 Aug 10. Review.

10.

Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.

Siroky BJ, Yin H, Babcock JT, Lu L, Hellmann AR, Dixon BP, Quilliam LA, Bissler JJ.

Am J Physiol Renal Physiol. 2012 Sep 15;303(6):F831-44. doi: 10.1152/ajprenal.00441.2011. Epub 2012 Jul 11.

11.

Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.

Yu J, Parkhitko AA, Henske EP.

Proc Am Thorac Soc. 2010 Feb;7(1):48-53. doi: 10.1513/pats.200909-104JS. Review.

12.

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.

Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN.

N Engl J Med. 2008 Jan 10;358(2):140-51. doi: 10.1056/NEJMoa063564.

13.

Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond.

Henske EP.

Pediatr Nephrol. 2005 Jul;20(7):854-7. Epub 2005 Apr 26. Review.

PMID:
15856327
14.

The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, Jansen A, Jóźwiak S, Kingswood JC, Kotulska K, Macaya A, Moavero R, Nabbout R, Zonnenberg BA.

Drugs. 2016 Apr;76(5):551-65. doi: 10.1007/s40265-016-0552-9. Review.

PMID:
26927950
15.

Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.

Franz DN.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1181-92. doi: 10.1586/era.11.93. Review.

PMID:
21916571
16.
17.

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Moavero R, Coniglio A, Garaci F, Curatolo P.

Ital J Pediatr. 2013 Sep 17;39:57. doi: 10.1186/1824-7288-39-57. Review.

18.

Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.

Curatolo P.

Pediatr Neurol. 2015 Mar;52(3):281-9. doi: 10.1016/j.pediatrneurol.2014.10.028. Epub 2014 Nov 20. Review.

PMID:
25591831
19.

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.

PMID:
19539245
20.

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.

Palavra F, Robalo C, Reis F.

Oxid Med Cell Longev. 2017;2017:9820181. doi: 10.1155/2017/9820181. Epub 2017 Mar 12. Review.

Supplemental Content

Support Center